StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Tyvyt (sintilimab) by Quarter

Tyvyt (sintilimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

QuarterlyAnnual

Eli Lilly Tyvyt (sintilimab): $136M in Q4 2024, up 19.7% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2024
136
Period ended Dec 31, 2024
Change on a year earlier
+19.7%
114 in Q4 2023
History
22 quarters
Since Q1 2019
Sources
14
Documents cited below

Where the Q4 2024 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2025-02-19) ↗

Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTyvyt (sintilimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
Q4 2024Dec 31, 2024136+19.7%Form 10-K (filed 2025-02-19) ↗
Q3 2024Sep 30, 2024150+30.5%Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024123+18.7%Form 10-Q (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024117+91.3%Form 10-Q (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023114+97.7%Form 10-K (filed 2025-02-19) ↗
Q3 2023Sep 30, 2023115+49.9%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023104+40.8%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 202361-28.7%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 202257.5-26.2%Form 10-K (filed 2025-02-19) ↗
Q3 2022Sep 30, 202276.8-38.9%Form 10-Q (filed 2022-11-01) ↗
Q2 2022Jun 30, 202273.6-29.9%Form 10-Q (filed 2022-08-04) ↗
Q1 2022Mar 31, 202285.5-22.1%Form 10-Q (filed 2022-04-29) ↗
Q4 2021Dec 31, 202177.9-24.2%Form 10-K (filed 2024-02-21) ↗
Q3 2021Sep 30, 2021126+48.8%Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 2021105+63.8%Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 2021110+91.1%Form 10-Q (filed 2022-04-29) ↗

Breakdown

What makes up tyvyt (sintilimab)

Cite this data

StockData. (2026). Eli Lilly Tyvyt (sintilimab) ($M), quarterly Q1 2019–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-tyvyt-ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.